100 results
8-K
EX-10.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
materials, including the exhibits thereto and documents incorporated by reference therein, together with the Pricing Prospectus and the Prospectus, being … , releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials
8-K
PCSA
Processa Pharmaceuticals Inc
16 Oct 23
Regulation FD Disclosure
9:15am
Materials”) that Processa Pharmaceuticals, Inc. (“Processa Pharmaceuticals”) intends to publish to its website, is attached to this Current Report on Form 8-K … and Exhibit 99.1. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While Processa Pharmaceuticals may elect
DEFA14A
PCSA
Processa Pharmaceuticals Inc
5 Oct 23
Additional proxy soliciting materials
10:01am
Statement
Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials …
Soliciting Materials Pursuant to §240.14a-12
Processa Pharmaceuticals, Inc.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy
DEFA14A
wealvc8qhvv nwy8n1v2
1 May 23
Additional proxy soliciting materials
10:01am
8-K
47s5ms
22 Dec 22
Regulation FD Disclosure
2:53pm
8-K
bxj6vave
6 Sep 22
Regulation FD Disclosure
9:46pm
8-K
klqzx ywwvlji6pp
14 Jul 22
Departure of Directors or Certain Officers
3:51pm
DEFA14A
otzhu7i 83uhy7j9gpc
31 May 22
Additional proxy soliciting materials
8:05am